Hepatitis C virus infection in patients with HIV-1: epidemiology, natural history and management

References

• Joint United Nations Programme on HIV/AIDS. World AIDS Day Report. 2011. Available from: www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2216_WorldAIDSday_report_2011_en.pdf
   Google Scholar
• Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17(2):107-15
   PubMed Web of Science ®Google Scholar
• Merchante N, Merino E, Lopez-Aldeguer J, et al. Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. Clin Infect Dis 2013;56(1):143-50
   PubMed Web of Science ®Google Scholar
• Weber R, Ruppik M, Rickenbach M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013;14(4):195-207
   PubMed Web of Science ®Google Scholar
• Limketkai BN, Mehta SH, Sutcliffe CG, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012;308(4):370-8
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Mehta SH, Torbenson MS, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007;21(16):2209-16
   PubMed Web of Science ®Google Scholar
• Carton JA, Collazos J, De La Fuente B, Asensi V. Course of liver fibrosis in HIV-hepatitis C virus-coinfected patients depending on the response to hepatitis C therapy. AIDS Res Hum Retroviruses 2013;29(2):215-22
   PubMed Web of Science ®Google Scholar
• Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009;49(1):22-31
   PubMed Web of Science ®Google Scholar
• Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292(23):2839-48
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; 2013. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf
   Google Scholar
• Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011;378(9791):571-83
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005;192(6):992-1002
   PubMed Web of Science ®Google Scholar
• Zhou J, Dore GJ, Zhang F, et al. Hepatitis B and C virus co-infection in The TREAT Asia HIV Observational Database. J Gastroenterol Hepatol 2007;22(9):1510-18
   PubMed Web of Science ®Google Scholar
• Petoumenos K, Ringland C; Australian HIVOD. Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database. HIV Med 2005;6(3):155-63
   PubMed Web of Science ®Google Scholar
• Backus LI, Boothroyd D, Deyton LR. HIV, hepatitis C and HIV/hepatitis C virus co-infection in vulnerable populations. AIDS 2005;19(Suppl 3):S13-19
   PubMed Web of Science ®Google Scholar
• Braitstein P, Justice A, Bangsberg DR, et al. Hepatitis C co-infection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort. AIDS 2006;20(3):323-31
   PubMed Web of Science ®Google Scholar
• Speers S, Klevens RM, Vonderwahl C, et al. Electronic matching of HIV/AIDS and hepatitis C surveillance registries in three states. Public Health Rep 2011;126(3):344-8
   PubMed Web of Science ®Google Scholar
• Taylor LE, Holubar M, Wu K, et al. Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials. Clin Infect Dis 2011;52(6):812-18
   PubMed Web of Science ®Google Scholar
• Perez Cachafeiro S, Caro-Murillo AM, Berenguer J, et al. Association of Patients' Geographic Origins with Viral Hepatitis Co-infection Patterns, Spain. Emerg Infect Dis 2011;17(6):1116-19
   PubMed Web of Science ®Google Scholar
• Labarga P, Soriano V, Caruz A, et al. Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. AIDS 2011;25(6):761-6
   PubMed Web of Science ®Google Scholar
• Hernando V, Perez-Cachafeiro S, Lewden C, et al. All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. J Hepatol 2012;57(4):743-51
   PubMed Web of Science ®Google Scholar
• Laufer N, Quarleri J, Bouzas MB, et al. Hepatitis B virus, hepatitis C virus and HIV co-infection among people living with HIV/AIDS in Buenos Aires, Argentina. Sex Transm Dis 2010;37(5):342-3
   PubMed Web of Science ®Google Scholar
• Sun HY, Chang SY, Yang ZY, et al. Recent hepatitis C virus infections in HIV-infected patients in Taiwan: incidence and risk factors. J Clin Microbiol 2012;50(3):781-7
   PubMed Web of Science ®Google Scholar
• Anggorowati N, Yano Y, Heriyanto DS, et al. Clinical and virological characteristics of hepatitis B or C virus co-infection with HIV in Indonesian patients. J Med Virol 2012;84(6):857-65
   PubMed Web of Science ®Google Scholar
• Mohammadi M, Talei G, Sheikhian A, et al. Survey of both hepatitis B virus (HBsAg) and hepatitis C virus (HCV-Ab) co-infection among HIV positive patients. Virol J 2009;6:202
   PubMed Web of Science ®Google Scholar
• Zhao YS, Su SI, Lv CX, et al. Seroprevalence of hepatitis C, hepatitis B virus and syphilis in HIV-1 infected patients in Shandong, China. Int J STD AIDS 2012;23(9):639-43
   PubMed Web of Science ®Google Scholar
• Bharti AR, Letendre SL, Wolfson T, et al. Clinical variables identify seronegative HCV co-infection in HIV-infected individuals. J Clin Virol 2011;52(4):328-32
   PubMed Web of Science ®Google Scholar
• Thomson EC, Nastouli E, Main J, et al. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS 2009;23(1):89-93
   PubMed Web of Science ®Google Scholar
• Thomson EC, Fleming VM, Main J, et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut 2011;60(6):837-45
   PubMed Web of Science ®Google Scholar
• European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS 2011;25(4):399-409
   PubMed Web of Science ®Google Scholar
• Orsetti E, Staffolani S, Gesuita R, et al. Changing characteristics and risk factors of patients with and without incident HCV infection among HIV-infected individuals. Infection 2013;41(5):987-90
   PubMed Web of Science ®Google Scholar
• Soriano V, Mocroft A, Rockstroh J, et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 2008;198(9):1337-44
   PubMed Web of Science ®Google Scholar
• Sofian M, Aghakhani A, Banifazl M, et al. Viral hepatitis and HIV infection among injection drug users in a central iranian city. J Addict Med 2012;6(4):292-6
   PubMed Web of Science ®Google Scholar
• Garten RJ, Zhang J, Lai S, et al. Co-infection with HIV and hepatitis C virus among injection drug users in southern China. Clin Infect Dis 2005;41(Suppl 1):S18-24
   Google Scholar
• Zhou YH, Yao ZH, Liu FL, et al. High prevalence of HIV, HCV, HBV and co-infection and associated risk factors among injecting drug users in Yunnan province, China. PLoS ONE 2012;7(8):e42937
   PubMed Web of Science ®Google Scholar
• Tanimoto T, Nguyen HC, Ishizaki A, et al. Multiple routes of hepatitis C virus transmission among injection drug users in Hai Phong. Northern Vietnam. J Med Virol 2010;82(8):1355-63
   PubMed Web of Science ®Google Scholar
• Bottieau E, Apers L, Van Esbroeck M, et al. Hepatitis C virus infection in HIV-infected men who have sex with men: sustained rising incidence in Antwerp. Belgium, 2001-2009. Euro Surveill 2010;15(39):19673
   PubMedGoogle Scholar
• Tseng YT, Sun HY, Chang SY, et al. Seroprevalence of hepatitis virus infection in men who have sex with men aged 18-40 years in Taiwan. J Formos Med Assoc 2012;111(8):431-8
   PubMed Web of Science ®Google Scholar
• Jin F, Prestage GP, Matthews G, et al. Prevalence, incidence and risk factors for hepatitis C in homosexual men: data from two cohorts of HIV-negative and HIV-positive men in Sydney, Australia. Sex Transm Infect 2010;86(1):25-8
   PubMed Web of Science ®Google Scholar
• Ruan Y, Qin G, Yin L, et al. Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study. AIDS 2007;21(Suppl 8):S39-46
   PubMed Web of Science ®Google Scholar
• Miller CL, Wood E, Spittal PM, et al. The future face of co-infection: prevalence and incidence of HIV and hepatitis C virus co-infection among young injection drug users. J Acquir Immune Defic Syndr 2004;36(2):743-9
   PubMed Web of Science ®Google Scholar
• Judd A, Hickman M, Jones S, et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ 2005;330(7481):24-5
   PubMed Web of Science ®Google Scholar
• Naggie S, Sulkowski MS. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology 2012;142(6):1324-34. e1323
   PubMed Web of Science ®Google Scholar
• Hagan H, Thiede H, Des Jarlais DC. HIV/hepatitis C virus co-infection in drug users: risk behavior and prevention. AIDS 2005;19(Suppl 3):S199-207
   PubMed Web of Science ®Google Scholar
• Van Den Berg CH, Smit C, Bakker M, et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol 2007;22(3):183-93
   PubMed Web of Science ®Google Scholar
• CDC. Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men – New York City, 2005-2010. MMWR Morb Mortal Wkly Rep 2011;60(28):945-50
   PubMedGoogle Scholar
• Van Der Helm JJ, Prins M, Del Amo J, et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS 2011;25(8):1083-91
   Google Scholar
• Yaphe S, Bozinoff N, Kyle R, et al. Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review. Sex Transm Infect 2012;88(7):558-64
   PubMed Web of Science ®Google Scholar
• Van De Laar T, Pybus O, Bruisten S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 2009;136(5):1609-17
   PubMed Web of Science ®Google Scholar
• Van De Laar TJ, Van Der Bij AK, Prins M, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 2007;196(2):230-8
   PubMed Web of Science ®Google Scholar
• Diamond C, Thiede H, Perdue T, et al. Viral hepatitis among young men who have sex with men: prevalence of infection, risk behaviors, and vaccination. Sex Transm Dis 2003;30(5):425-32
   PubMed Web of Science ®Google Scholar
• Alary M, Joly JR, Vincelette J, et al. Lack of evidence of sexual transmission of hepatitis C virus in a prospective cohort study of men who have sex with men. Am J Public Health 2005;95(3):502-5
   PubMed Web of Science ®Google Scholar
• Jin F, Prestage GP, Kippax SC, et al. Prevalence and risk factors of hepatitis C in HIV-negative homosexual men in Sydney, Australia. Aust NZ J Public Health 2005;29(6):536-9
   PubMed Web of Science ®Google Scholar
• Hao C, Yan H, Yang H, et al. The incidence of syphilis, HIV and HCV and associated factors in a cohort of men who have sex with men in Nanjing. China. Sex Transm Infect 2011;87(3):199-201
   PubMed Web of Science ®Google Scholar
• Briat A, Dulioust E, Galimand J, et al. Hepatitis C virus in the semen of men coinfected with HIV-1: prevalence and origin. AIDS 2005;19(16):1827-35
   PubMed Web of Science ®Google Scholar
• Marx MA, Murugavel KG, Tarwater PM, et al. Association of hepatitis C virus infection with sexual exposure in southern India. Clin Infect Dis 2003;37(4):514-20
   PubMed Web of Science ®Google Scholar
• Danta M, Rodger AJ. Transmission of HCV in HIV-positive populations. Curr Opin HIV AIDS 2011;6(6):451-8
   PubMed Web of Science ®Google Scholar
• Schmidt AJ, Rockstroh JK, Vogel M, et al. Trouble with bleeding. risk factors for acute hepatitis C among HIV-positive gay men from Germany – a case-control study. PLoS ONE 2011;6(3):e17781
   PubMed Web of Science ®Google Scholar
• Matthews GV, Hellard M, Haber P, et al. Characteristics and treatment outcomes among HIV-infected individuals in the Australian trial in acute hepatitis C. Clin Infect Dis 2009;48(5):650-8
   PubMed Web of Science ®Google Scholar
• Obermeier M, Ingiliz P, Weitner L, et al. Acute hepatitis C in persons infected with the human immunodeficiency virus (HIV). the “real-life setting” proves the concept. Eur J Med Res 2011;16(5):237-42
   PubMed Web of Science ®Google Scholar
• Larsen C, Chaix ML, Le Strat Y, et al. Gaining greater insight into HCV emergence in HIV-infected men who have sex with men. the HEPAIG Study. PLoS ONE 2011;6(12):e29322
   PubMed Web of Science ®Google Scholar
• Bolcic F, Laufer N, Trinchero J, et al. A clustering phenomenon among HCV-1a strains among patients coinfected with HIV from Buenos Aires, Argentina. J Med Virol 2012;84(4):570-81
   PubMed Web of Science ®Google Scholar
• Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection. a meta-analysis. Clin Infect Dis 2001;33(4):562-9
   PubMed Web of Science ®Google Scholar
• Klein MB, Rollet KC, Saeed S, et al. HIV and hepatitis C virus co-infection in Canada: challenges and opportunities for reducing preventable morbidity and mortality. HIV Med 2013;14(1):10-20
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Peters L, Grint D, et al. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV? J Hepatol 2013;59(2):213-20
   PubMed Web of Science ®Google Scholar
• Piroth L, Larsen C, Binquet C, et al. Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study. Hepatology 2010;52(6):1915-21
   PubMed Web of Science ®Google Scholar
• Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol 2008;103(5):1283-97. quiz 1298
   PubMed Web of Science ®Google Scholar
• Nattermann J, Timm J, Nischalke HD, et al. The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5Delta32 mutation. J Hepatol 2011;55(6):1201-6
   PubMed Web of Science ®Google Scholar
• Lunge VR, Da Rocha DB, Beria JU, et al. IL28B polymorphism associated with spontaneous clearance of hepatitis C infection in a Southern Brazilian HIV type 1 population. AIDS Res Hum Retroviruses 2012;28(2):215-19
   PubMed Web of Science ®Google Scholar
• Van Den Berg CH, Grady BP, Schinkel J, et al. Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS ONE 2011;6(11):e27555
   Web of Science ®Google Scholar
• Harfouch S, Guiguet M, Valantin MA, et al. Lack of TGF-beta production by hepatitis C virus-specific T cells during HCV acute phase is associated with HCV clearance in HIV co-infection. J Hepatol 2012;56(6):1259-68
   PubMed Web of Science ®Google Scholar
• Harcourt G, Gomperts E, Donfield S, Klenerman P. Diminished frequency of hepatitis C virus specific interferon gamma secreting CD4+ T cells in human immunodeficiency virus/hepatitis C virus coinfected patients. Gut 2006;55(10):1484-7
   PubMed Web of Science ®Google Scholar
• Flynn JK, Dore GJ, Matthews G, et al. Impaired hepatitis C virus (HCV)-specific interferon-gamma responses in individuals with HIV who acquire HCV infection. correlation with CD4+ T-Cell Counts. J Infect Dis 2012;206(10):1568-76
   PubMed Web of Science ®Google Scholar
• Schnuriger A, Dominguez S, Guiguet M, et al. Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. AIDS 2009;23(16):2079-89
   PubMed Web of Science ®Google Scholar
• Danta M, Semmo N, Fabris P, et al. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis 2008;197(11):1558-66
   PubMed Web of Science ®Google Scholar
• Reiberger T, Aberle JH, Kundi M, et al. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV co-infection. Antivir Ther 2008;13(8):969-76
   PubMed Web of Science ®Google Scholar
• Kim AY, Chung RT. Co-infection with HIV-1 and HCV – a one-two punch. Gastroenterology 2009;137(3):795-814
   PubMed Web of Science ®Google Scholar
• Montes-De-Oca M, Blanco MJ, Marquez M, et al. Haemodynamic derangement in human immunodeficiency virus-infected patients with hepatitis C virus-related cirrhosis: the role of bacterial translocation. Liver Int 2011;31(6):850-8
   PubMed Web of Science ®Google Scholar
• Salmon D, Bani-Sadr F, Loko MA, et al. Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients. results from ANRS CO13 HEPAVIH. J Hepatol 2012;56(4):862-8
   PubMed Web of Science ®Google Scholar
• Merchante N, Rivero A, De Los Santos-Gil I, et al. Insulin resistance is associated with liver stiffness in HIV/HCV co-infected patients. Gut 2009;58(12):1654-60
   PubMed Web of Science ®Google Scholar
• Halfon P, Penaranda G, Carrat F, et al. Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients. Aliment Pharmacol Ther 2009;30(1):61-70
   PubMed Web of Science ®Google Scholar
• Sandler NG, Koh C, Roque A, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 2011;141(4):1220-30. 1230.e1221-3
   PubMed Web of Science ®Google Scholar
• Vali B, Jones RB, Sakhdari A, et al. HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. Eur J Immunol 2010;40(9):2493-505
   PubMed Web of Science ®Google Scholar
• Feuth T, Arends JE, Fransen JH, et al. Complementary role of HCV and HIV in T-cell activation and exhaustion in HIV/HCV co-infection. PLoS ONE 2013;8(3):e59302
   Web of Science ®Google Scholar
• Korner C, Tolksdorf F, Riesner K, et al. Hepatitis C co-infection enhances sensitization of CD4(+) T-cells towards Fas-induced apoptosis in viraemic and HAART-controlled HIV-1-positive patients. Antivir Ther 2011;16(7):1047-55
   PubMed Web of Science ®Google Scholar
• Graham CS, Curry M, He Q, et al. Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV. Hepatology 2004;40(1):125-32
   PubMed Web of Science ®Google Scholar
• Morishima C, Shuhart MC, Yoshihara CS, et al. Preservation of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses despite global loss of CD4+ T cells in HCV/HIV co-infection. J Infect Dis 2007;196(4):577-86
   PubMed Web of Science ®Google Scholar
• Alatrakchi N, Graham CS, He Q, et al. CD8+ cell responses to hepatitis C virus (HCV) in the liver of persons with HCV-HIV co-infection versus HCV monoinfection. J Infect Dis 2005;191(5):702-9
   PubMed Web of Science ®Google Scholar
• Barrett L, Gallant M, Howley C, et al. Stronger hepatitis C virus-specific CD8+ T-cell responses in HIV co-infection. J Viral Hepat 2011;18(3):170-80
   PubMed Web of Science ®Google Scholar
• Jang JY, Shao RX, Lin W, et al. HIV infection increases HCV-induced hepatocyte apoptosis. J Hepatol 2011;54(4):612-20
   PubMed Web of Science ®Google Scholar
• Tuyama AC, Hong F, Saiman Y, et al. Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Hepatology 2010;52(2):612-22
   PubMed Web of Science ®Google Scholar
• Bruno R, Galastri S, Sacchi P, et al. gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis. Gut 2010;59(4):513-20
   PubMed Web of Science ®Google Scholar
• Hong F, Saiman Y, Si C, et al. X4 human immunodeficiency virus type 1 gp120 promotes human hepatic stellate cell activation and collagen I expression through interactions with CXCR4. PLoS ONE 2012;7(3):e33659
   Web of Science ®Google Scholar
• Neukam K, Garcia-Rey S, Cifuentes C, et al. HIV-co-infection leads to a modest increase in plasma HCV-RNA load in patients with chronic HCV infection. Antiviral Res 2012;95(3):212-15
   PubMed Web of Science ®Google Scholar
• Vispo E, Fernandez-Montero JV, Labarga P, et al. Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients. AIDS 2013;27(7):1187-8
   PubMed Web of Science ®Google Scholar
• Blanco F, Barreiro P, Ryan P, et al. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. J Viral Hepat 2011;18(1):11-16
   PubMed Web of Science ®Google Scholar
• Suarez-Zarracina T, Valle-Garay E, Collazos J, et al. Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients. J Viral Hepat 2012;19(10):685-93
   PubMed Web of Science ®Google Scholar
• Berenguer J, Bellon JM, Miralles P, et al. Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus co-infection. Clin Infect Dis 2008;46(1):137-43
   PubMed Web of Science ®Google Scholar
• Neukam K, Mira JA, Ruiz-Morales J, et al. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients. J Antimicrob Chemother 2011;66(11):2605-14
   PubMed Web of Science ®Google Scholar
• Rallon NI, Soriano V, Restrepo C, et al. HCV-specific T-cell responses in HIV/hepatitis C virus-coinfected patients on highly active antiretroviral therapy are comparable to those observed in hepatitis C virus-monoinfected individuals. J Acquir Immune Defic Syndr 2011;57(1):1-8
   PubMed Web of Science ®Google Scholar
• Chen TY, Ding EL, Seage Iii GR, Kim AY. Meta-analysis. increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009;49(10):1605-15
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Moore RD, Mehta SH, et al. Hepatitis C and progression of HIV disease. JAMA 2002;288(2):199-206
   PubMed Web of Science ®Google Scholar
• Collazos J, Carton JA, Asensi V. Evaluation of the possible influence of hepatitis C virus and liver fibrosis on HIV type 1 immunological and virological outcomes. HIV Med 2011;12(5):308-15
   PubMed Web of Science ®Google Scholar
• Kang W, Li Y, Zhuang Y, et al. Dynamic analysis of Th1/Th2 cytokine concentration during antiretroviral therapy of HIV-1/HCV co-infected patients. BMC Infect Dis 2012;12:102
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Wei X, Li Y, et al. HCV co-infection does not alter the frequency of regulatory T cells or CD8+ T cell immune activation in chronically infected HIV+ Chinese subjects. AIDS Res Hum Retroviruses 2012;28(9):1044-51
   PubMed Web of Science ®Google Scholar
• Sajadi MM, Pulijala R, Redfield RR, Talwani R. Chronic immune activation and decreased CD4 cell counts associated with hepatitis C infection in HIV-1 natural viral suppressors. AIDS 2012;26(15):1879-84
   PubMed Web of Science ®Google Scholar
• Berenguer J, Rodriguez E, Miralles P, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. Clin Infect Dis 2012;55(5):728-36
   PubMed Web of Science ®Google Scholar
• Laguno M, Martinez-Rebollar M, Perez I, et al. Low rate of sustained virological response in an outbreak of acute hepatitis C in HIV-infected patients. AIDS Res Hum Retroviruses 2012;28(10):1294-300
   PubMed Web of Science ®Google Scholar
• Vogel M, Dominguez S, Bhagani S, et al. Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort. Antivir Ther 2010;15(2):267-79
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351(5):438-50
   PubMed Web of Science ®Google Scholar
• Neumann A, Polis M, Rozenberg L, et al. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients. AIDS 2007;21(14):1855-65
   PubMed Web of Science ®Google Scholar
• Aguilar Marucco D, Veronese L, De Requena DG, et al. Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus. J Antimicrob Chemother 2007;59(3):565-8
   PubMed Web of Science ®Google Scholar
• Investigators ST, Fidler S, Porter K, et al. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med 2013;368(3):207-17
   PubMed Web of Science ®Google Scholar
• Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012;308(4):387-402
   PubMed Web of Science ®Google Scholar
• Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012;13(Suppl 2):1-85
   Google Scholar
• Rodriguez-Novoa S, Morello J, Gonzalez M, et al. Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. AIDS 2008;22(18):2535-7
   PubMed Web of Science ®Google Scholar
• Hulskotte EG, Feng HP, Xuan F, et al. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis 2013;56(5):718-26
   PubMed Web of Science ®Google Scholar
• Hammond KP, Wolfe P, Burton JR Jr, et al. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers. J Acquir Immune Defic Syndr 2013;62(1):67-73
   PubMed Web of Science ®Google Scholar
• Garg V, Chandorkar G, Yang Y, et al. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. Br J Clin Pharmacol 2013;75(2):431-9
   PubMed Web of Science ®Google Scholar
• Mira JA, Lopez-Cortes LF, Barreiro P, et al. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother 2008;62(6):1365-73
   PubMed Web of Science ®Google Scholar
• Solas C, Pambrun E, Winnock M, et al. Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction? AIDS 2012;26(17):2193-9
   PubMed Web of Science ®Google Scholar
• Cooper C, La Porte C, Tossonian H, et al. A pilot, prospective, open-label simplification study to evaluate the safety, efficacy, and pharmacokinetics of once-daily lopinavir-ritonavir monotherapy in HIV-HCV coinfected patients: the MONOCO study. HIV Clin Trials 2012;13(4):179-88
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011;55(2):245-64
   PubMed Web of Science ®Google Scholar
• Van Den Eynde E, Crespo M, Esteban JI, et al. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial. Clin Infect Dis 2009;48(8):1152-9
   PubMed Web of Science ®Google Scholar
• Sulkowski MS. Viral hepatitis and HIV co-infection. J Hepatol 2008;48(2):353-67
   PubMed Web of Science ®Google Scholar
• Labarga P, Barreiro P, Da Silva A, et al. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-alpha for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial. J Infect Dis 2012;206(6):961-8
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV. a randomized trial. Ann Intern Med 2013;159(2):86-96
   PubMed Web of Science ®Google Scholar
• Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV. a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013;13(7):597-605
   PubMed Web of Science ®Google Scholar
• Cotte L, Braun J, Lascoux-Combe C, et al. High early virological response with telaprevir-pegylated-interferon-ribavirin in treatment-experienced hepatitis C virus genotype 1/HIV co-infected patients: ANRS HC26 TelapreVIH Study. Presented at: 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013); 3 – 6 March 2013; Atlanta, GA, USA
   Google Scholar
• Deterding K, Gruner N, Buggisch P, et al. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis 2013;13(6):497-506
   PubMed Web of Science ®Google Scholar
• European Aids Treatment Network Acute Hepatitis C Infection Consensus Panel. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS 2011;25(4):399-409
   PubMed Web of Science ®Google Scholar
• Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004;18(13):F27-36
   Web of Science ®Google Scholar
• Martin-Carbonero L, Nunez M, Marino A, et al. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS 2008;22(1):15-21
   PubMed Web of Science ®Google Scholar
• Dore GJ, Torriani FJ, Rodriguez-Torres M, et al. Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection. AIDS 2007;21(12):1555-9
   PubMed Web of Science ®Google Scholar
• Dayyeh BK, Gupta N, Sherman KE, et al. Aids Clinical Trials Group A5178 Study Team. IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy. PLoS ONE 2011;6(10):e25753
   Web of Science ®Google Scholar
• Aparicio E, Parera M, Franco S, et al. IL28B SNP rs8099917 is strongly associated with pegylated interferon-alpha and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS ONE 2010;5(10):e13771
   Web of Science ®Google Scholar
• Rallon NI, Lopez-Fernandez LA, Garcia MI, et al. Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients. AIDS 2013;27(5):687-96
   PubMed Web of Science ®Google Scholar
• Grebely J, Hellard M, Applegate T, et al. Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection. AIDS 2012;26(13):1653-61
   PubMed Web of Science ®Google Scholar
• Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41(10):1100-4
   PubMed Web of Science ®Google Scholar
• Payer BA, Reiberger T, Aberle J, et al. IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients. Eur J Clin Invest 2012;42(6):599-606
   PubMed Web of Science ®Google Scholar
• De Araujo ES, Dahari H, Cotler SJ, et al. Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2011;56(2):95-9
   PubMed Web of Science ®Google Scholar
• Jimenez-Sousa MA, Berenguer J, Rallon N, et al. IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients. J Viral Hepat 2013;20(5):358-66
   PubMed Web of Science ®Google Scholar
• Rivero-Juarez A, Camacho A, Caruz A, et al. LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients. AIDS 2012;26(8):1009-15
   PubMed Web of Science ®Google Scholar
• Neukam K, Camacho A, Caruz A, et al. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. J Hepatol 2012;56(4):788-94
   PubMed Web of Science ®Google Scholar
• Nattermann J, Vogel M, Nischalke HD, et al. Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C. J Infect Dis 2011;203(5):595-601
   PubMed Web of Science ®Google Scholar
• Poordad F, Mccone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1195-206
   PubMed Web of Science ®Google Scholar
• Dieterich D, Rockstroh J, Orkin C, et al. Simeprevir with Pegylated Interferon/Ribavirin in Patients Co-infected with Chronic Hepatitis C Virus and HIV-1: Week-24 Interim Analysis of the TMC435-C212 Study. Presented at: 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013); 3 - 6 March 2013; Atlanta, GA, USA
   Google Scholar
• Dieterich D, Soriano V, Nelson M, et al. STARTVerso 4. High rates of early virologic response in hepatitis C virus genotype 1/HIV co-infected patients treated with faldaprevir + pegylated interferon and ribavirin. Presented at: 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013); 3 - 6 March 2013; Atlanta, GA, USA
   Google Scholar
• Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368(20):1867-77
   PubMed Web of Science ®Google Scholar
• Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 2013;58(1):428-38
   PubMed Web of Science ®Google Scholar
• Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365(11):1014-24
   PubMed Web of Science ®Google Scholar
• Benito JM, Sanchez-Parra C, Maida I, et al. Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir. Antivir Ther 2013;18(5):709-15
   PubMed Web of Science ®Google Scholar
• Susser S, Vermehren J, Forestier N, et al. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol 2011;52(4):321-7
   PubMed Web of Science ®Google Scholar
• Romano KP, Ali A, Aydin C, et al. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog 2012;8(7):e1002832
   PubMed Web of Science ®Google Scholar
• Lam AM, Espiritu C, Bansal S, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2012;56(6):3359-68
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013;381(9883):2100-7
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Sustained virologic response with daclatasvir plus sofosbuvir ± ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC). Presented at: 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013); 24 - 28 April 2013; Amsterdam, Netherlands
   Google Scholar
• Pelosi LA, Voss S, Liu M, et al. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob Agents Chemother 2012;56(10):5230-9
   PubMed Web of Science ®Google Scholar
• Fierer D. Telaprevir for acute hepatitis C virus in HIV+ men both shortens treatment and improves outcome. Presented at: 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013); 3 - 6 March 2013; Atlanta, GA, USA
   Google Scholar
• Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus co-infection. Liver Transpl 2012;18(6):716-26
   PubMed Web of Science ®Google Scholar
• Kemmer NM, Sherman KE. Liver transplantation trends in the HIV population. Dig Dis Sci 2011;56(11):3393-8
   PubMed Web of Science ®Google Scholar
• Anadol E, Beckebaum S, Radecke K, et al. Orthotopic liver transplantation in human-immunodeficiency-virus-positive patients in Germany. AIDS Res Treat 2012;2012:197501
   PubMedGoogle Scholar
• Miro JM, Montejo M, Castells L, et al. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. Am J Transplant 2012;12(7):1866-76
   PubMed Web of Science ®Google Scholar
• Gutierrez-Moreno M, Bernal-Bellido C, Suarez-Artacho G, et al. Spontaneous clearance of HCV in HIV-Hepatitis C virus coinfected liver transplant patients: prospective study. Transplant Proc 2012;44(7):2100-2
   PubMed Web of Science ®Google Scholar
• Samri A, Roque-Afonso AM, Beran O, et al. Preservation of immune function and anti-hepatitis C virus (HCV) immune responses after liver transplantation in HIV-HCV coinfected patients (ANRS-HC08 "THEVIC" trial). J Hepatol 2009;51(6):1000-9
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Hughes EA, Bifano M, et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013;13(6):1601-5
   PubMed Web of Science ®Google Scholar
• Baccarani U, Adani GL, Bragantini F, et al. Long-term outcomes of orthotopic liver transplantation in human immunodeficiency virus-infected patients and comparison with human immunodeficiency virus-negative cases. Transplant Proc 2011;43(4):1119-22
   PubMed Web of Science ®Google Scholar
• Bahirwani R, Barin B, Olthoff K, et al. Chronic kidney disease after liver transplantation in human immunodeficiency virus/hepatitis C virus-coinfected recipients versus human immunodeficiency virus-infected recipients without hepatitis C virus: results from the national institutes of health multi-site study. Liver Transpl 2013;19(6):619-26
   PubMed Web of Science ®Google Scholar